Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Significant Drop in Short Interest

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the target of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 62,600 shares, a decrease of 67.2% from the March 31st total of 190,800 shares. Based on an average daily volume of 461,600 shares, the short-interest ratio is presently 0.1 days.

Provectus Biopharmaceuticals Price Performance

Shares of OTCMKTS:PVCT traded up $0.00 during trading on Thursday, hitting $0.20. The company had a trading volume of 251,000 shares, compared to its average volume of 289,478. The company has a fifty day simple moving average of $0.18 and a two-hundred day simple moving average of $0.13. Provectus Biopharmaceuticals has a one year low of $0.06 and a one year high of $0.22.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis.